S

SAB

Develops fully human polyclonal antibodies

Facilities Technician

Full-TimeUpdated on 10/21/2026
No salary listed
Junior
Sioux Falls, SD, USA
In Person
General Maintenance & RepairBuilding & Property Maintenance

About the job

Requirements
  • A high school diploma or equivalent and additional technical or related education or training are required.
  • At least 2 years of experience in facilities management, laboratory operations, or a related field are required; experience in a biotech or pharmaceutical environment is a plus, and relevant experience in other FDA-regulated industries may be acceptable.
  • Ability to stay focused on tasks and multitask safely and compliantly in a regulated environment.
  • Strong understanding of laboratory safety protocols and regulatory requirements, including OSHA, EPA, and FDA requirements.
  • Proficiency using Microsoft Office applications, including Word, Excel, PowerPoint, and Outlook.
  • Ability to write technical reports detailing procedures, outcomes, and observations.
  • Ability to walk, stand, and sit regularly; lift or move up to 25–30 pounds regularly and occasionally up to 50 pounds with assistance; and use close and peripheral vision and adjust focus.
Responsibilities
  • Support the Facilities Manager in the daily operation, maintenance, and continuous improvement of laboratory, office, warehouse, and facility systems.
  • Assist with day-to-day operation and maintenance of laboratory, office, warehouse, and support areas.
  • Perform routine facility inspections to identify maintenance needs, safety concerns, and operational deficiencies.
  • Support preventive and corrective maintenance activities for building systems.
  • Respond to work orders and facility service requests in a timely manner.
  • Troubleshoot facility-related issues and escalate concerns to the Facilities Manager when necessary.
  • Maintain facility appearance and functionality through routine inspections and upkeep activities.
  • Assist with setup and organization of laboratory workspaces, including benchtops, equipment, and storage areas.
  • Assist with management of equipment calibration and maintenance schedules to ensure performance and regulatory compliance.
  • Assist in monitoring facility systems, including HVAC, compressed air, automation, electrical systems and generators, plumbing, emergency backup systems, monitoring systems, and equipment.
  • Document and report abnormal operating conditions.
  • Assist with utility monitoring and trending activities.
  • Support laboratory personnel with equipment troubleshooting, basic repairs, relocation, installation, and setup as required.
  • Maintain accurate maintenance records and work order documentation.
  • Assist with standard operating procedure implementation and compliance activities.
  • Support facility audits, inspections, and regulatory assessments.
  • Coordinate vendors and contractors during repairs, verify completed work, communicate findings, and record activities.
Desired Qualifications
  • An associate’s degree or equivalent in a related field is desirable but not required.
  • Experience working with laboratory equipment and instrumentation is a plus.

About the company

SAB Biotherapeutics uses the DiversitAb platform to produce fully human polyclonal antibodies in genetically engineered transchromosomic cattle, removing the need for human donors. These antibodies are designed to treat immunology disorders and infectious diseases and include programs like SAB-142 for Type 1 Diabetes, SAB-176 for severe influenza, and SAB-195 for C. difficile infection. The platform can shorten development timelines, aiming to move candidates from concept to clinic in under five months, and it focuses on polyclonal antibodies rather than monoclonal ones. The company pursues regulatory approval and commercialization through collaborations with government agencies, academia, and pharmaceutical partners to address high-need diseases and biodefense applications.

Company Size

51-200

Company Stage

IPO

Headquarters

Miami Beach, Florida

Founded

2014

Get referred to SAB

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Over 60 SAFEGUARD sites were active by August 2026, accelerating enrollment.
  • Part A completed in Q1 2026, and Part B targets 159 patients.
  • SAB still expects runway through 2028, reducing near-term financing risk.

What critics are saying

  • SAB burned through another $85 million in March 2026, signaling relentless dilution pressure.
  • SAFEGUARD data arrive in 2H 2027; any efficacy miss destroys the T1D story.
  • One-program dependence makes SAB existentially fragile if SAB-142 fails or FDA demands a new trial.

What makes SAB unique

  • SAB BIO's Tc cattle platform generates fully human polyclonal antibodies without human donors.
  • SAB-142 entered registrational Phase 2b SAFEGUARD in March 2026, de-risking the lead program.
  • Sanofi joined SAB's July 2025 $175 million financing, validating the platform commercially.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

3%

2 year growth

0%
Investing.com
Mar 18th, 2026
SAB Biotherapeutics prices $85M stock offering at $3.85/share By Investing.com

SAB Biotherapeutics prices $85M stock offering at $3.85/share

Seeking Alpha
Mar 17th, 2026
SAB Biotherapeutics launches stock offering to fund SAB-142 diabetes treatment; shares fall 6.9%

SAB Biotherapeutics has launched an underwritten public offering of common stock and pre-funded warrants. The company is offering securities directly, with underwriters having the option to purchase up to 15% additional securities within 30 days. Proceeds will primarily fund development of SAB-142, the company's lead candidate for Type 1 Diabetes. The funds will also support clinical trials, manufacturing, regulatory activities and general corporate expenses. Shares fell 6.9% in post-market trading following the announcement.

Associated Press
Mar 9th, 2026
SAB BIO raises $175M, advances T1D therapy SAB-142 into registrational Phase 2b trial

SAB Biotherapeutics has reported full year 2025 financial results whilst advancing its lead candidate SAB-142 for type 1 diabetes. The company raised $175 million in an oversubscribed private placement including strategic investor Sanofi, providing operational runway through 2028. SAB has dosed multiple patients in its registrational Phase 2b SAFEGUARD study, with enrollment on track to complete by end of 2026 and topline data expected in second half of 2027. Phase 1 data released in December 2025 confirmed SAB-142's favourable safety profile, showing no serum sickness and low immunogenicity across all cohorts. The company ended 2025 with cash and securities of $143.5 million. Research and development expenses were $34.4 million, up from $30.3 million in 2024.

Money Controller
Jul 21st, 2025
SAB Biotherapeutics: $175M Private Placement Announced

SAB Biotherapeutics announced an oversubscribed $175 million private placement with participation from Sanofi and other investors. The funds will support the Phase 2b SAFEGUARD study of SAB-142 for autoimmune T1D and extend the cash runway to mid-2028. The deal includes issuing Series B nonvoting convertible preferred stock and warrants for potential additional proceeds of $284 million. The private placement is expected to close on July 22, 2025, subject to conditions.

GlobeNewswire
Jul 21st, 2025
SAB BIO Announces Oversubscribed $175 Million Private Placement

SAB BIO Announces Oversubscribed $175 Million Private Placement...